References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailEffects of 3 months of short sessions of controlled whole body vibrations on the risk of falls among nursing home residents
Beaudart, Charlotte ULg; Maquet, Didier ULg; Mannarino, Mélanie et al

in BMC Geriatrics (2013), 13(42),

Background: Fatigue, lack of motivation and low compliance can be observed in nursing home residents during the practice of physical activity. Because exercises should not be too vigorous, whole body ... [more ▼]

Background: Fatigue, lack of motivation and low compliance can be observed in nursing home residents during the practice of physical activity. Because exercises should not be too vigorous, whole body vibration could potentially be an effective alternative. The objective of this randomized controlled trial was to assess the impact of 3-month training by whole body vibration on the risk of falls among nursing home residents. Methods: Patients were randomized into two groups: the whole body vibration group which received 3 training sessions every week composed of 5 series of only 15 seconds of vibrations at 30 Hz frequency and a control group with normal daily life for the whole study period. The impact of this training on the risk of falls was assessed blindly by three tests: the Tinetti Test, the Timed Up and Go test and a quantitative evaluation of a 10-second walk performed with a tri-axial accelerometer. Results: 62 subjects (47 women and 15 men; mean age 83.2 ± 7.99 years) were recruited for the study. No significant change in the studied parameters was observed between the treated (n=31) and the control group (n=31) after 3 months of training by controlled whole-body-vibrations. Actually, the Tinetti test increased of + 0.93 ± 3.14 points in the treated group against + 0.88 ± 2.33 points in the control group (p = 0.89 when adjusted). The Timed Up and Go test showed a median evolution of - 1.14 (− 4.75-3.73) seconds in the treated group against + 0.41 (− 3.57- 2.41) seconds in the control group (p = 0.06). For the quantitative evaluation of the walk, no significant change was observed between the treated and the control group in single task as well as in dual task conditions. Conclusions: The whole body vibration training performed with the exposition settings such as those used in this research was feasible but seems to have no impact on the risk of falls among nursing home residents. Further investigations, in which, for example, the exposure parameters would be changed, seem necessary [less ▲]

Detailed reference viewed: 31 (15 ULg)
Full Text
Peer Reviewed
See detailRelationship between use of antidepressants and risk of fractures: a meta-analysis
Rabenda, Véronique ULg; Nicolet, Delphine ULg; Beaudart, Charlotte ULg et al

in Osteoporosis International (2013), 24

Summary It has been shown that antidepressants would have a direct action on bone metabolism and would be associated with increased fracture risk. Results from this large meta-analysis show that both ... [more ▼]

Summary It has been shown that antidepressants would have a direct action on bone metabolism and would be associated with increased fracture risk. Results from this large meta-analysis show that both SSRIs and TCAs are associated with a moderate and clinically significant increase in the risk of fractures of all types. Introduction This study seeks to investigate the relationship between use of antidepressants and the risk of fracture. Methods An exhaustive systematic research of case–control and cohort studies published or performed between 1966 and April 2011 that reported risk estimates of fracture associated with use of antidepressants was performed using MEDLINE, PsycINFO, and the Cochrane Systematic Review Database, manual review of the literature, and congressional abstracts. Inclusion, quality scoring, and data abstraction were performed systematically by three independent reviewers. Results A total of 34 studies (n01,217,464 individuals) were identified. Compared with non-users, the random effects pooled RR of fractures of all types, among antidepressant users, were 1.39 (95%CI 1.32–1.47). Use of antidepressants were associated with a 42 %, 47 %, and 38 % risk increase in non-vertebral, hip, and spine fractures, respectively ([For non-vertebral fractures: RR01.42, 95%CI 1.34–1.51]; [For hip fractures: RR01.47, 95%CI 1.36–1.58]; [For spine fractures: RR01.38, 95%CI 1.19–1.61]). Studies examining SSRI use showed systematically a higher increase in the risk of fractures of all types, non-vertebral, and hip fractures than studies evaluating TCA use. Conclusions Results from this large meta-analysis show that both SSRIs and TCAs are associated with a moderate and clinically significant increase in the risk of fractures of all types. [less ▲]

Detailed reference viewed: 46 (23 ULg)
Full Text
Peer Reviewed
See detailEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal women.
Kanis, J. A.; McCloskey, E. V.; Johansson, H. et al

in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2013), 24(1), 23-57

Guidance is provided in a European setting on the assessment and treatment of postmenopausal women at risk of fractures due to osteoporosis. INTRODUCTION: The International Osteoporosis Foundation and ... [more ▼]

Guidance is provided in a European setting on the assessment and treatment of postmenopausal women at risk of fractures due to osteoporosis. INTRODUCTION: The International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published guidance for the diagnosis and management of osteoporosis in 2008. This manuscript updates these in a European setting. METHODS: Systematic literature reviews. RESULTS: The following areas are reviewed: the role of bone mineral density measurement for the diagnosis of osteoporosis and assessment of fracture risk, general and pharmacological management of osteoporosis, monitoring of treatment, assessment of fracture risk, case finding strategies, investigation of patients and health economics of treatment. CONCLUSIONS: A platform is provided on which specific guidelines can be developed for national use. [less ▲]

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailTreatment of osteoporosis in men.
Kaufman, JM; Reginster, Jean-Yves ULg; Boonen, S et al

in BONE (2013), 53(1), 134-44

SUMMARY: Aspects of osteoporosis in men, such as screening and identification strategies, definitions of diagnosis and intervention thresholds, and treatment options (both approved and in the pipeline ... [more ▼]

SUMMARY: Aspects of osteoporosis in men, such as screening and identification strategies, definitions of diagnosis and intervention thresholds, and treatment options (both approved and in the pipeline) are discussed. INTRODUCTION: Awareness of osteoporosis in men is improving, although it remains under-diagnosed and under-treated. A European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) workshop was convened to discuss osteoporosis in men and to provide a report by a panel of experts (the authors). METHODS: A debate with an expert panel on preselected topics was conducted. RESULTS AND CONCLUSIONS: Although additional fracture data are needed to endorse the clinical care of osteoporosis in men, consensus views were reached on diagnostic criteria and intervention thresholds. Empirical data in men display similarities with data acquired in women, despite pathophysiological differences, which may not be clinically relevant. Men should receive treatment at a similar 10-year fracture probability as in women. The design of mixed studies may reduce the lag between comparable treatments for osteoporosis in women becoming available in men. [less ▲]

Detailed reference viewed: 12 (3 ULg)
Full Text
Peer Reviewed
See detailIs there potential for strontium ranelate in the management of osteoarthritis ?
Reginster, Jean-Yves ULg; Pelousse, Franz; Bruyère, Olivier ULg

in Clinical Practice (2013), 10(2), 201-207

Detailed reference viewed: 23 (8 ULg)
Full Text
Peer Reviewed
See detailEquivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study.
Zegels, Brigitte ULg; Crozes, P.; Uebelhart, D. et al

in Osteoarthritis and Cartilage (2013), 21(1), 22-27

OBJECTIVE: Evaluation of the efficacy and safety of a single oral dose of a 1200 mg sachet of chondroitin 4&6 sulfate (CS 1200) vs three daily capsules of chondroitin 4&6 sulfate 400 mg (CS 3*400 ... [more ▼]

OBJECTIVE: Evaluation of the efficacy and safety of a single oral dose of a 1200 mg sachet of chondroitin 4&6 sulfate (CS 1200) vs three daily capsules of chondroitin 4&6 sulfate 400 mg (CS 3*400) (equivalence study) and vs placebo (superiority study) during 3 months, in patients with knee osteoarthritis (OA). DESIGN: Comparative, double-blind, randomized, multicenter study, including 353 patients of both genders over 45 years with knee OA. Minimum inclusion criteria were a Lequesne index (LI) >/= 7 and pain >/= 40 mm on a visual analogue scale (VAS). LI and VAS were assessed at baseline and after 1-3 months. Equivalence between CS was tested using the per-protocol procedure and superiority of CS vs placebo was tested using an intent-to-treat procedure. RESULTS: After 3 months of follow-up, no significant difference was demonstrated between the oral daily single dose of CS 1200 formulation and the three daily capsules of CS 400. Patients treated with CS 1200 or CS 3*400 were significantly improved compared to placebo after 3 months of follow-up in terms of LI (<0.001) and VAS (P < 0.01). No significant difference in terms of security and tolerability was observed between the three groups. CONCLUSION: This study suggests that a daily administration of an oral sachet of 1200 mg of chondroitin 4&6 sulfate allows a significant clinical improvement compared to a placebo, and a similar improvement when compared to a regimen of three daily capsules of 400 mg of the same active ingredient. [less ▲]

Detailed reference viewed: 14 (9 ULg)
Full Text
See detailDetection of specific nitrated markers
REGINSTER, Jean-Yves ULg; DEBERG, Michelle ULg; Henrotin, Yves ULg et al

Patent (2012)

Detailed reference viewed: 10 (6 ULg)
Full Text
Peer Reviewed
See detailOstéomalacie hypophosphatémique hyperphosphaturique avec hypersécrétion de FGF-23
COLSON, Laurent ULg; Vander Rest, Catherine; Reginster, Jean-Yves ULg et al

in Lettre du Rhumatologue (La) (2012), 387

Detailed reference viewed: 105 (35 ULg)
Full Text
See detailNécessité de nouveaux critères de remboursement pour traiter l'ostéoporose en Belgique
Bruyère, Olivier ULg; Bergmann, Pierre; Body, Jean-Jacques et al

in Ortho-Rhumato (2012), 10(5), 3

Detailed reference viewed: 28 (4 ULg)
Full Text
Peer Reviewed
See detailRole of glucosamine in the treatment for osteoarthritis.
REGINSTER, Jean-Yves ULg; Neuprez, Audrey ULg; LECART, Marie-Paule ULg et al

in Rheumatology International (2012), 32(10), 2959-67

Over the last 20 years, several studies have investigated the ability of glucosamine sulfate to improve the symptoms (pain and function) and to delay the structural progression of osteoarthritis. There is ... [more ▼]

Over the last 20 years, several studies have investigated the ability of glucosamine sulfate to improve the symptoms (pain and function) and to delay the structural progression of osteoarthritis. There is now a large, convergent body of evidence that glucosamine sulfate, given at a daily oral dose of 1,500 mg, is able to significantly reduce the symptoms of osteoarthritis in the lower limbs. This dose of glucosamine sulfate has also been shown, in two independent studies, to prevent the joint space narrowing observed at the femorotibial compartment in patients with mild-to-moderate knee osteoarthritis. This effect also translated into a 50 % reduction in the incidence of osteoarthritis-related surgery of the lower limbs during a 5-year period following the withdrawal of the treatment. Some discrepancies have been described between the results of studies performed with a patent-protected formulation of glucosamine sulfate distributed as a drug and those having used glucosamine preparations purchased from global suppliers, packaged, and sold over-the-counter as nutritional supplements. [less ▲]

Detailed reference viewed: 69 (24 ULg)
Full Text
Peer Reviewed
See detailRelationships Between Changes in Bone Mineral Density or Bone Turnover Markers and Vertebral Fracture Incidence in Patients Treated with Bazedoxifene
Bruyère, Olivier ULg; Detilleux, Johann ULg; Chines, Arkadi et al

in Calcified Tissue International (2012), 91(4), 244-9

We analyzed the relationships between bone mineral density (BMD) or bone turnover marker (BTM) changes and vertebral fracture incidence in women treated with bazedoxifene using a post hoc analysis from a ... [more ▼]

We analyzed the relationships between bone mineral density (BMD) or bone turnover marker (BTM) changes and vertebral fracture incidence in women treated with bazedoxifene using a post hoc analysis from a 3-year randomized, placebo-controlled study evaluating the effect of bazedoxifene (20 or 40 mg) on fracture risk reduction. BMD was assessed at baseline and every 6 months for 3 years. Osteocalcin and C-telopeptide of type I collagen were assessed at baseline and at 3, 12, and 36 months. Vertebral fractures were assessed with a semiquantitative visual assessment. Data were available for 5,244 women, of whom 3,476 were treated with bazedoxifene. Using a logistic regression analysis and the classical Li approach, the proportion of fracture incidence explained by BMD change after 3 years of bazedoxifene treatment was 29 % for the total hip and 44 % for the femoral neck. The proportion of treatment explained by lumbar BMD change could not be quantified accurately because of the significant interaction between treatment and change in BMD. With the same model, the 12-month BTM changes explained up to 29 % of the fracture risk reduction observed with the two forms of bazedoxifene. In women treated with bazedoxifene, changes in femoral neck BMD, hip BMD, or BTMs explained a moderate proportion of the fracture risk reduction observed during the 3 years of follow-up. However, BMD or BTM changes cannot be recommended for individual monitoring of women treated with bazedoxifene. [less ▲]

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailHealth-related quality of life after total knee or hip replacement for osteoarthritis: a 7-year prospective study
Bruyère, Olivier ULg; Ethgen, Olivier ULg; Neuprez, Audrey ULg et al

in Archives of Orthopaedic & Trauma Surgery (2012)

Objective To assess health-related quality of life (HRQOL) in a prospective study with 7 years of follow-up in 49 consecutive patients who underwent a total joint replacement because of osteoarthritis ... [more ▼]

Objective To assess health-related quality of life (HRQOL) in a prospective study with 7 years of follow-up in 49 consecutive patients who underwent a total joint replacement because of osteoarthritis. Methods Generic HRQOL was assessed with the shortform 36 (SF-36) and specific HRQOL with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Results Out of the 39 subjects who have completed the 7 years of follow-up of this study, 22 (56.4 %) underwent a hip replacement surgery and the other 17 (43.6 %) a knee replacement. Six months after surgery, a significant improvement, compared to preoperative scores, was observed in two of the eight dimensions of the SF-36 (i.e. physical function and pain). The same dimensions, pain and physical function, at the same time, 6 months after surgery, measured by the WOMAC, showed a significant improvement as well, but there was no significant change in the stiffness score. From 6 months to the end of followup, changes in SF-36 scores showed a significant improvement in physical function (p = 0.008), role-physical (p = 0.004) and role-emotional (p = 0.01) while all scores of the WOMAC improved (p\0.001 for pain, p\0.001 for stiffness and p\0.01 for physical function). Conclusion The improvements observed in HRQOL at short term after surgery, are at least maintained over a 7-year follow-up period. [less ▲]

Detailed reference viewed: 50 (21 ULg)
Full Text
Peer Reviewed
See detailTranslation validation of a new back pain screening questionnaire (the STarT Back Screening Tool) in French
Bruyère, Olivier ULg; Demoulin, Maryline ULg; Brereton, Clara ULg et al

in Archives of Public Health (2012), 70

Background: Low back pain (LBP) is a major public health problem and the identification of individuals at risk of persistent LBP poses substantial challenges to clinical management. The STarT Back ... [more ▼]

Background: Low back pain (LBP) is a major public health problem and the identification of individuals at risk of persistent LBP poses substantial challenges to clinical management. The STarT Back questionnaire is a validated nine-item patient self-report questionnaire that classifies patients with LBP at low, medium or high-risk of poor prognosis for persistent non-specific LBP. The objective of this study was to translate and cross-culturally adapt the English version of the STarT Back questionnaire into French. Methods: The translation was performed using best practice translation guidelines. The following phases were performed: contact with the STarT Back questionnaire developers, initial translations (English into French), synthesis, back translations, expert committee review, test of the pre-final version on 44 individuals with LBP, final version. Results: The linguistic translation required minor semantic alterations. The participants interviewed indicated that all items of the questionnaire were globally clear and comprehensible. However, 6 subjects (14%) wondered if two questions were related to back pain or general health. After discussion within the expert committee and with the developer of the STarT Back tool, it was decided to modify the questionnaire and to add a reference to back pain in these two questions. Conclusions: The French version of the STarT Back questionnaire has been shown to be comprehensible and adapted to the French speaking general population. Investigations are now required to test the psychometric properties (reliability, internal and external validity, responsiveness) of this translated version of the questionnaire. [less ▲]

Detailed reference viewed: 71 (20 ULg)
Full Text
Peer Reviewed
See detailSevere prevalent vertebral fractures predict subsequent vertebral and nonvertebral fractures: a 3-year prospective study
Bruyère, Olivier ULg; Roux, Christian; Nicolet, Delphine ULg et al

in Annals of the Rheumatic Diseases (2012, June), 71(Suppl.3), 588

Detailed reference viewed: 17 (5 ULg)
Full Text
Peer Reviewed
See detailPerception, knowledge and use by general practitioners of Belgium of the FRAX tool
Bruyère, Olivier ULg; Nicolet, Delphine ULg; Compère, Stéphanie et al

in Annals of the Rheumatic Diseases (2012, June), 71(Suppl.3), 716

Detailed reference viewed: 19 (4 ULg)
Full Text
Peer Reviewed
See detailSeverity of incident vertebral fracture and future fracture risk: a 3-year prospective study
Bruyère, Olivier ULg; Roux, Christian; Nicolet, Delphine ULg et al

in Annals of the Rheumatic Diseases (2012, June), 71(Suppl.3), 716

Detailed reference viewed: 26 (5 ULg)
Full Text
Peer Reviewed
See detailRadiological and clinical profil of osteoarthritic patients undergoing of total joint replacement
Neuprez, Audrey ULg; François, Garance ULg; Bruyère, Olivier ULg et al

in Annals of the Rheumatic Diseases (2012, June), 71(Suppl.3), 693

Detailed reference viewed: 39 (15 ULg)
Full Text
Peer Reviewed
See detailAssessment of quality of life in patients undergoing total joint replacement for OA of the lower limb
Neuprez, Audrey ULg; François, Garance ULg; Bruyère, Olivier ULg et al

in Annals of the Rheumatic Diseases (2012, June), 71(Suppl.3), 693

Detailed reference viewed: 45 (10 ULg)